
# Inflammatory Disease Pipeline

		<b>Pre-Clinical</b>	Phase 1	Phase 2	Phase 3	NDA/MAA
Filgotinib JAK-1 inhibitor (GS-6034)	Rheumatoid arthritis					Approved for RA in EU & Japan, CRL receive
Filgotinib JAK-1 inhibitor (GS-6034)	Ulcerative colitis					
Filgotinib JAK-1 inhibitor (GS-6034)	Crohn's disease					
Filgotinib JAK-1 inhibitor (GS-6034)	Psoriatic arthritis					
Filgotinib JAK-1 inhibitor (GS-6034)	Ankylosing spondylitis					
Filgotinib JAK-1 inhibitor (GS-6034)	Uveitis					
TPL2 inhibitor (GS-4875)	Ulcerative colitis					
ADAMTS-5 Inhibitor (GLPG-1972) <sup>1</sup>	Osteoarthritis					
BIRAK4 inhibitor (GS-5718)	IBD					
GLF G-3312	Inflammatory diseases				Toledo Cor	npound Note: '3312 no longer actively developed
GLPG-3970 <sup>1</sup> GLPG-3667 <sup>1</sup> GLPG-3121 <sup>1</sup> GLPG-0555 <sup>1</sup> GLPG-0555 <sup>1</sup> GLPG-0555 <sup>1</sup>	Inflammatory diseases				Toledo Cor	
GLPG-3667 <sup>1</sup>	Inflammatory diseases					
GLPG-3121 <sup>1</sup>	Inflammatory diseases					
© GLPG-0555 <sup>1</sup>	Osteoarthritis					
= α4β7 inhibitor (GS-1427)	IBD					
Small molecule inh. (Neutrophil target)	Inflammatory diseases					
Small molecule inh. (Innate immunity target)	Inflammatory diseases					
GLPG-4399 <sup>1</sup>	Inflammatory diseases				Toledo Cor	npound
GLPG-4259 <sup>1</sup>	Inflammatory diseases					·
GLPG-4471 <sup>1</sup>	Inflammatory diseases					
GLPG-4059 <sup>1</sup>	T2D					
Cilofexor FXR agonist (GS-9674)	PSC					
Ziritaxestat ATX inhibitor (GLPG-1690) <sup>2</sup>	IPF					
Cilofexor, firsocostat combination <sup>3</sup>	NASH					
Selonsertib ASK1 inhibitor (GS-4997)	DKD					
Ziritaxestat ATX inhibitor (GLPG-1690) <sup>2</sup>	Systemic sclerosis				positive Ph	2a topline √
	IPF				•	·
GLPG-1205 <sup>1</sup> GLPG-4124 <sup>1</sup>	Fibrosis					
€ GLPG-3535 <sup>1</sup>	Fibrosis					
GLPG-4586 <sup>1</sup>	Fibrosis					
GLPG-4605 <sup>1</sup>	Fibrosis				Toledo Cor	mpound

<sup>1</sup> Optionable partner program. 2 Optioned partner program 3 Combination of cilofexor FXR agonist and firsocostat ACC inhibitor (selonsertib no longer included). IPF - Idiopathic Pulmonary Fibrosis. T2D - Type 2 Diabetes Mellitis. Selected pre-clinical assets displayed.









#### **Early pipeline**

30 validated targets

15 programs in LO

7
preclinical candidate
programs

'4471 – inflammation

'4399 – inflammation

'4259 – inflammation

'4124 – fibrosis

'4059 – metabolic

'4586 – fibrosis

'4605 – fibrosis

4 Ph1 programs

'3970 – inflammation

'3667 – inflammation


`555 – inflammation

'2737 – kidney disease



## **Filgotinib**


#### potential for 5 launches in next 4 years




RA: rheumatoid arthritis; CD: Crohn's disease; UC: ulcerative colitis; AS: ankylosing spondylitis; PSA: psoriatic arthritis



### **IPF & fibrosis portfolio**



# Toledo: robust activity in *in vivo* models



green: preclinical activity; orange: insufficient preclinical activity Note: '3312 no longer actively developed



# Galápagos Pioneering for patients

We discover We dare We care